CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo

Stock News01-30

CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. ("Demai Pharma," an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), received approval from the National Medical Products Administration (NMPA) of China on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is intended for the treatment of non-segmental vitiligo with facial involvement in patients 12 years of age and older, representing the first and only targeted drug approved in China for vitiligo treatment, thereby addressing a significant unmet clinical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1192355574?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 12:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192355574","market":"other","top_or_hot":-1,"title":"CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo","media":"Stock News","content":"<p>CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. (\"Demai Pharma,\" an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), received approval from the National Medical Products Administration (NMPA) of China on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is intended for the treatment of non-segmental vitiligo with facial involvement in patients 12 years of age and older, representing the first and only targeted drug approved in China for vitiligo treatment, thereby addressing a significant unmet clinical need.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMS (00867): Innovative Drug Ruxolitinib Phosphate Cream Approved in China, Marking First and Only Targeted Therapy for Vitiligo\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-30 12:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. (\"Demai Pharma,\" an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), received approval from the National Medical Products Administration (NMPA) of China on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is intended for the treatment of non-segmental vitiligo with facial involvement in patients 12 years of age and older, representing the first and only targeted drug approved in China for vitiligo treatment, thereby addressing a significant unmet clinical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1593","symbol_name":"医美概念股","start_time":0,"source_url":"","article_id":"1192355574","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192355574","pubTimestamp":1769746818,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. (\"Demai Pharma,\" an innovative pharmaceutical company specializing in dermatological health that is applying for an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1593":"医美概念股","BK1161":"生物科技","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK1574":"生物医药B类股","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","00867":"康哲药业","06978":"永泰生物-B","BK1191":"制药","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD"},"translate_title":"康哲药业（00867）：创新药磷酸芦可替尼乳膏在中国获批，标志着首个也是唯一一个白癜风靶向疗法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"00867":1},"content_text":"CMS (00867) announced that its subsidiary, Demai Pharmaceutical Co., Ltd. (\"Demai Pharma,\" an innovative pharmaceutical company specializing in dermatological health that is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited), received approval from the National Medical Products Administration (NMPA) of China on January 30, 2026, for the New Drug Application (NDA) of Ruxolitinib Phosphate Cream (for the vitiligo indication). The product is intended for the treatment of non-segmental vitiligo with facial involvement in patients 12 years of age and older, representing the first and only targeted drug approved in China for vitiligo treatment, thereby addressing a significant unmet clinical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1192355574","isCrawlerRequest":true}